Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

159.46 -1.18 (-0.74%)
Streaming Delayed Price Updated: 1:35 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Johnson & Johnson (JNJ) Q3 2023 Earnings Call Transcript
JNJ earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine
Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical... 
Via Benzinga
Iran Warning Stops The Market Rally Buy Historic Biden Visit To Israel Is A Positive For The Market
To gain an edge, this is what you need to know today. 
Via Benzinga
Johnson & Johnson Is Falling, but This Tech Stock Is Really Getting Hit Hard
Earnings season is starting to ramp up. 
Via The Motley Fool
Johnson & Johnson Raises Outlook As The Health Care Bellwether Beats Views
The company beat third-quarter forecasts and raised its outlook for the year. It's now focusing on innovative drugs and medtech following its consumer health spinoff. 
Via Investor's Business Daily
Johnson & Johnson Earnings Preview
Via Benzinga
Johnson & Johnson Resumed The Bearish Cycle
Johnson & Johnson (JNJ) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. 
Via Talk Markets
Peering Into Johnson & Johnson's Recent Short Interest
Via Benzinga
New Johnson & Johnson's Q3 Earnings Beat Street View, Raises Annual Outlook
Johnson & Johnson (NYSE: JNJ) has reported Q3 FY23 adjusted earnings of $2.66 per share, up 19.3% Y/Y and beating the conse 
Via Benzinga
Topics Earnings
Exposures Financial
US Stock Futures Slide As Traders Look Past Positive Earnings News Flow; Analysts Predict Year-End Rally And Strong 2024 Ahead
Via Benzinga
Earnings Scheduled For October 17, 2023
Companies Reporting Before The Bell • Goldman Sachs Gr (NYSE:GS) is projected to report quarterly earnings at $5.31 per share on revenue of $11.14 billion. 
Via Benzinga
Bank of America, Johnson & Johnson And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
2 No-Brainer Dividend King Stocks to Buy Right Now
These two blue-chip stocks should hold up well in a choppy market. 
Via The Motley Fool
Johnson & Johnson Unusual Options Activity
Via Benzinga
Pendulum Swings: Markets Recover Slightly After Friday's Anxious Trading, But Middle East Worries Dominate
(Monday market open) Last week gave us a taste of earnings. The meal starts tomorrow and picks up steam as banks, airlines, and health care companies report. 
Via Benzinga
Monday's Market Minute: This Week's Focus: Earnings & Consumer Spending
The focus for investors and traders will shift from inflation after the higher-than-expected figures last week to earnings and consumer spending habits. 
Via Benzinga
Topics Economy
Exposures Interest Rates
4 Dividend Stocks Yielding 4% or More to Buy Without Hesitation
These stocks offer attractive payouts that should rise in the future. 
Via The Motley Fool
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
US Stocks On Track For A Strong Start To Week, Buoyed By Earnings Optimism: Analyst Flags 13-14% Upside As Bull Market Enters Its Second Year
US stocks appear on track to start higher on Monday as traders look ahead to the earnings season to serve as upside catalyst. 
Via Benzinga
Tesla, Netflix Grab Earnings Spotlight This Week As Analysts Divided On Q3 Reporting Season: What's On Investors' Radar?
While analysts look forward to the unfolding reporting season with guarded optimism, they are skeptical regarding forward guidance. 
Via Benzinga
Johnson & Johnson Stock: Is Now the Time to Sell?
Conservative investors buy Johnson & Johnson for the dividend, but that payout is less safe after its Kenvue spinoff 
Via InvestorPlace
3 Dividend Growth Stocks You Can Buy and Hold Forever
Investors can sit back and let the dividends flow in with these great stocks. 
Via The Motley Fool
Israel-Hamas War Shakes Middle East, Inflation Reawakens, Oil Surges: The Week In The Markets
Higher-than-expected inflation data this week caught markets off guard, and the Israel-Hamas conflict is sending the markets running to safer assets. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Over Delivering: Big Banks Beat Expectations After Tough Quarter, But Market Eyes Middle East Warily
(Friday market open) Big bank earnings this morning threatened to take a back seat as geopolitical worries helped spark a rally in crude oil and sent more investors fleeing toward the perceived safety... 
Via Benzinga
Exposures Fossil Fuels
Beat the Market With These 7 Warren Buffett Stocks
Although it’s not the most exciting concept ever, these Warren Buffett stocks can help you win in an uncertain market. 
Via InvestorPlace
7 High-Growth S&P 500 Stocks to Buy Now
Although industry stalwarts don’t typically offer robust profitability potential, these high-growth S&P 500 stocks might change your tune. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Dow ETF In Focus Ahead Of Q3 Earnings
The Dow Jones Industrial Average Index has struggled over the past three months, shedding 1.6%. Worries over longer-than-expected higher interest rates and a weakening Chinese economy have weighed on... 
Via Talk Markets
Topics ETFs Economy Stocks
Exposures Economy US Equities
Eli Lilly Treatment For Crohn's Tops Placebo In Latest Study, Makes Plans For 2024
Eli Lilly And Co (NYSE: LLY) plans to submit a marketing application for a drug that treats Crohn's disease to the Food and Drug Administration (FDA) in 2024. 
Via Benzinga
3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI’
These are the AI stocks to buy and hold for multibagger returns in the next 24 months, as they represent quality growth companies. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Meet the 3 Dividend Kings Warren Buffett Is Betting $21 Billion On
Three dividend stocks that have each increased their base annual payout for more than 60 years account for $21 billion of Berkshire Hathaway's $337 billion of invested assets. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.